According to the Food and Drug Administration announced it was investigating possible links between widely used hormonal prostrate cancer drugs and an alight rise in risk for diabetes and heart disease, thousands of men who rely on these drugs to extend their were left wondering what to do next. Dr. Mark Solo way, chair of urology at the University Of Miami Miller School Of Medicine, "Clearly these drugs are needed for the treatment of prostate cancer. Lowering the male hormone is by far the most effective treatment; there should be more judgment in prescribing GnRH agonists."

Dr. Nelson Neal Stone, a clinical professor of urology and radiation oncology at Mount Sinai of Medicine in New York City agreed, "There is evidence that low testosterone can induce metabolic syndrome. When I speak to patients who have to go on these agents, I counsel them about the risks of increased weight gain and I tell them they need to monitor their carbohydrate intake and increase their amount of exercise, and they can decrease the risk of developing metabolic syndrome". The FDA said six studies showed a small increased risk of diabetes or heart disease in patient's treated with the drugs when compared with other prostate cancer therapies. An agency said, "However, these studies have design limitations that make it difficult to confirm a cause-and-effect relationship".

The FDA said the studies included limited information about drug exposure, varying definitions for heart disease, missing data on heart disease risk factors and other problems. Company spokeswoman Emmy Tsui said, "The Company "remains confident in the overall safety profile of Eligard based on clinical trials and post-marketing surveillance". The FDA further advised that patients should not stop taking the drugs unless a doctor tells them to.